PHASE-I AND PHARMACOLOGIC STUDY OF 72-HOUR INFUSED 5-FLUOROURACIL IN MAN

被引：19

作者：

BYFIELD, JE

FRANKEL, SS

HORNBECK, CL

SHARP, TR

CALLIPARI, FB

FLOYD, RA

机构：

[1] UNIV CALIF SAN DIEGO,SCH MED,DIV RADIAT ONCOL,LA JOLLA,CA 92093

[2] VET ADM MED CTR,DEPT RADIOL,SAN DIEGO,CA 92161

[3] VET ADM MED CTR,DIV LAB SERV & PHARM,SAN DIEGO,CA 92161

[4] SAN DIEGO TUMOR INST,SAN DIEGO,CA

来源：

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 1985年 / 8卷 / 05期

关键词：

D O I：

10.1097/00000421-198510000-00017

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：429 / 440

页数：12

共 39 条

[1]

ALMERSJO O, 1976, European Surgical Research, V8, P489, DOI 10.1159/000127895

[2]

ALMERSJO OE, 1980, ACTA PHARMACOL TOX, V46, P329

[3]

BAGSHAW MA, 1961, AMER J ROENTGENOL RA, V85, P822

[4]

BARONE RM, 1982, CANCER, V50, P850, DOI 10.1002/1097-0142(19820901)50:5<850::AID-CNCR2820500508>3.0.CO

[5]

2-2

[6]

BYFIELD JE, 1983, CANCER TREAT REP, V67, P933

[7] PHARMACOLOGIC REQUIREMENTS FOR OBTAINING SENSITIZATION OF HUMAN-TUMOR CELLS-INVITRO TO COMBINED 5-FLUOROURACIL OR FTORAFUR AND X-RAYS [J].

BYFIELD, JE ;

CALABROJONES, P ;

KLISAK, I ;

KULHANIAN, F .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1982, 8 (11) :1923-1933

[8]

BYFIELD JE, 1983, CANCER TREAT REP, V67, P709

[9]

BYFIELD JE, 1980, CANCER-AM CANCER SOC, V45, P703, DOI 10.1002/1097-0142(19800215)45:4<703::AID-CNCR2820450415>3.0.CO

[10]

2-Q

← 1 2 3 4 →